- Quotes
- Dashboard
- Chart
- Historical Prices
- Options
- News & PR
- News
- Market Currents
- Press Releases
- Coverage
- Cramer
- Top Analysts
- Business Intelligence
- Transcripts
- Events
- Key Developments
- Earnings
- History & Projected
- Consensus
- Peer Earnings
- Filings
- SEC Filings
- Annual Report
- Financials
- Income Statement
- Balance Sheet
- Cash Flow
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
BPAX Market Currents
more »
-
March 20 BioSante Pharmaceuticals (BPAX) announces positive results from studies of its Pill-Plus oral contraceptive. The company is line to receive royalty payments on sales of Pill-Plus if it's eventually introduced in the U.S. Shares +14.1% premarket.
Comment![On the Move, Healthcare]
BPAX in Focus
more »
BPAX Related Articles
more »
BPAX News
more »
-
at MarketWatch.com (Feb 15, 2012)
-
at MarketWatch.com (Dec 14, 2011)
-
at CNBC.com (Jun 14, 2011)
-
at MarketWatch.com (May 31, 2011)
-
at MarketWatch.com (Apr 13, 2011)
BPAX Press Releases and Filings
more »
-
Business Wire (May 8, 2012)
-
Business Wire (Apr 17, 2012)
-
Business Wire (Mar 20, 2012)
-
Business Wire (Mar 13, 2012)
-
Business Wire (Dec 14, 2011)
BPAX Latest Transcript
more »
Currently, there are no transcripts for BPAX.
BPAX Cramer
more »
Currently, there are no Cramer articles on BPAX.
BPAX Instablog posts
more »
BPAX vs. ETF Alternatives
Company Description
We are a specialty pharmaceutical company focused on developing products for female sexual health, menopause, contraception and male hypogonadism. Our primary products are gel formulations of testosterone and estradiol. We also are engaged in the development of our proprietary calcium... More
